Core Viewpoint - The announcement highlights a strategic cooperation agreement between Sillodic Pharmaceuticals and Kaito Bio, focusing on the development of mRNA-based therapies utilizing Sillodic's proprietary AI+mRNA research platform and lipid nanoparticle delivery system [1] Group 1: Strategic Cooperation - Sillodic Pharmaceuticals entered into a strategic cooperation framework agreement with Kaito Bio on August 20, 2025 [1] - The collaboration aims to leverage Sillodic's self-developed AI+mRNA research platform and lipid nanoparticle delivery system (3D-LNP) alongside Kaito Bio's expertise in large-scale mRNA production [1] - The partnership will enhance cooperation in targeted LNP delivery (tLNP), tumor vaccines, and in vivo CAR-T/NK therapies, with specific implementations to follow in formal agreements [1] Group 2: Technological Advancements - Sillodic Pharmaceuticals has established a globally recognized mRNA technology platform and LNP delivery system [1] - The mRNA technology platform is built on advanced AI technology, featuring a multi-module tumor vaccine analysis platform (3D-PreciseAg) that supports extensive antigen multi-omics analysis and optimal tumor antigen selection [1] - The AI-enhanced LNP delivery technology platform allows for the screening of thousands of compounds through AI algorithms, resulting in various LNP products that improve delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK therapies while significantly reducing toxicity [1]

Group 1 - The core viewpoint of the news is that Sidodi Pharmaceutical has entered into a strategic cooperation framework agreement with Kaito Bio to enhance their collaboration in the mRNA field, leveraging their respective strengths in AI+mRNA research and large-scale mRNA production [1] - The collaboration will focus on targeted LNP delivery, tumor vaccines, and in vivo CAR-T/NK therapies, indicating a significant step in Sidodi Pharmaceutical's commitment to mRNA research and development [1] - This partnership aims to provide robust capacity support for the clinical development and future commercialization of innovative therapies based on mRNA-LNP technology [1] Group 2 - Sidodi Pharmaceutical has established a globally recognized mRNA technology platform and LNP delivery system, which is built on advanced AI technology [2] - The mRNA technology platform includes a multi-module tumor vaccine analysis platform (3D-PreciseAg) that supports extensive antigen multi-omics analysis and the selection of tumor antigens [2] - The company possesses an AI-enhanced LNP delivery technology platform that utilizes AI algorithms to screen thousands of compounds, improving the delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK therapies while significantly reducing toxicity [2]

Group 1 - The company, Shenlian Biopharmaceutical, announced the successful integration of self-assembling nanoparticle technology with circular mRNA technology to develop the world's first circular mRNA vaccine for swine fever, achieving significant progress [1] - The research results have been published in the internationally recognized immunology journal, "Frontiers in Immunology," indicating the credibility and scientific validation of the findings [1] - The new vaccine is expected to innovate in both antibody persistence and production cost, providing a novel solution for swine fever purification [1] Group 2 - The traditional swine fever E2 subunit vaccine has been crucial in swine fever purification due to its excellent biosafety characteristics and the ability to distinguish between infected and immune animals, but high production costs have limited its widespread application [1] - The company has developed a new generation of swine fever E2 glycoprotein vaccine using a self-built mRNA-LNP technology platform, which combines high immunogenicity with cost-effectiveness [1] - The research team compared different cationic lipid formulations in cmRNA-LNP preparations, finding that the AX4-LNP formulation induced superior cellular and humoral immunity compared to other cationic lipids [1] Group 3 - The study successfully constructed a modular cmRNA-LNP platform integrated with mi3 nanoparticles, overcoming the technical limitations of traditional subunit vaccines and achieving synergistic enhancement of humoral and cellular immunity [2] - This technology not only provides a new generation solution for the development of swine viral vaccines but also has the potential to be expanded to other animal disease vaccines [2]